A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. · 2000
Read A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. by Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. (2000) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2363506.txt.
Introduction
Yung and colleagues compared two oral drugs for a brain tumor that had come back in 2000. The tumor was glioblastoma multiforme, the most aggressive form of brain cancer. Patients whose cancer returned after first treatment have few options, and the trial tested temozolomide against an older drug, procarbazine.
The randomised study enrolled 225 patients at many centres. With temozolomide, 21% of patients reached six months without their cancer growing, versus 8% on procarbazine, a gap the trial judged significant. Median time before growth was 12.4 weeks on temozolomide and about 8.3 weeks on the older drug, and six-month survival was 60% versus 44% in the same comparison. Quality of life held up while the disease stayed controlled, whichever drug patients took. Side effects were mostly mild or moderate.
Catalog record
| CREATOR | Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. |
|---|---|
| YEAR | 2000 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse By W K A Yung, R E Albright, J Olson, R Fredericks, K Fink, M D Prados, M Brada, A Spence, R J Hohl, W Shapiro, M Glantz, H Greenberg Published in: British Journal of Cancer DOI: 10.1054/bjoc.2000.1316 ABSTRACT A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2/day or 150 mg/m2/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2/day or 125 mg/m2/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign Glioblastoma multiforme (GBM) is the most common and malig- nant primary brain tumour (Chamberlain and Kormanik, 1998). Standard treatment for the initial treatment of these tumours is surgical resection and postoperative radiation. A meta-analysis of randomized clinical trials reports a modest survival advantage with adjuvant chemotherapy (Fine et al, 1993). However, a recent Medical Research Council randomized trial of 674 patients failed to show a survival benefit of nitrosourea-based adjuvant chemotherapy (Brada et al, 1998). Regardless of initial treatment, most patients relapse (Feun et al, 1994). Single-agent or combina- tion salvage chemotherapy regimens for recurrent high-grade glioma remain palliative; median survival is 6 to 8 months, and few patients survive more than 2 years (Forsyth, 1996; Chamberlain and Kormarik 1998). Temozolomide (TMZ) is a new orally administered, second- generation imidazotetrazine prodrug with essentially 100% oral bioavailability (Newlands et al, 1992). Preclinically, TMZ demon- strated broad spectrum, schedule dependent, antitumour activity with relatively little toxicity. TMZ spontaneously converts to the active alkylating agent 5-(3-methyltriazen-1-yl) imidazole-4- carboximide under physiologic conditions (Stevens et al, 1987; Tsang et al, 1990) with extensive tissue distribution, including penetration of the blood-brain barrier and the cerebrospinal fluid (Patel et al, 1995; Brock et al, 1996, 1997). In phase I and II clin- ical studies, TMZ was well tolerated with a favourable toxicity profile, with easily managed noncumulative myelotoxicity. TMZ has notable antitumour activity against recurrent GBM, recurrent anaplastic astrocytoma, and advanced malignant melanoma, and A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse WKA Yung1 , RE Albright2 , J Olson3 , R Fredericks4 , K Fink5 , MD Prados 6 , M Brada7 , A Spence8 , RJ Hohl9 , W Shapiro10 , M Glantz11 , H Greenberg12 , RG Selker13 , NA Vick14 , R Rampling15 , H Friedman16 , P Phillips17 , J Bruner1 , N Yue18 , D Osoba19 , S Zaknoen20 and VA Levin1 1 UTMD Anderson Cancer Center, Department of Neuro-Oncology, Box 100, 1515 Holcombe Boulevard, Houston, Texas 77030; 2 Barret Cancer Center, 234 Goodman Street, Cincinnati, Ohio 45267; 3 Emory University, Department of Neurosurgery, 1327 Clifton Road, Atlanta, Georgia 30322; 4 University of Mississippi Medical Center, 2500 North State Street, Jackson, Mississippi 39216; 5 University of Texas, Southwestern Medical School, Department of Neurology, 5323 Harry Hines Boulevard, Dallas, Texas 75235; 6 University of California, San Francisco, Department of Neurosurgery, 533 Parnassus Street, Room U107, San Francisco, California 94143; 7 The Royal Marsden NHS Trust and the Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, United Kingdom; 8 University of Washington, Department of Neurology, Box 356465, 1959 N.E. Pacific Street, Seattle, Washington 98195; 9 University of Iowa, Hospitals and Clinics, 200 Hawkins Drive, Iowa City, Iowa 52242; 10 Barrow Neurological Institute, Division of Neurology, 350 West Thomas Road, Phoenix, Arizona 85013; 11 Memorial Hospital of Rhode Island, 710 Robinson Road, PO Box 665, Hinsdale, Massachusetts 01235; 12 University of Michigan Medical Center, Department of Neurology, 1500 East Medical Center Drive, 1914 Taubman Center, Box 0316, Ann Arbor, Michigan 48109; 13 West Penn Hospital, Center for Neuro-Oncology, 4800 Friendship Avenue - Suite 1614, Pittsburgh, Pennsylvania 15224; 14 Evanston Hospital, Division of Neurology, 2650 Ridge Avenue, Evanston, Illinois 60201; 15 Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, United Kingdom; 16 Duke University Medical Center, Department of Pediatric Hematology-Oncology, Duke North - Room 5418, Erwin Road, Durham, North Carolina 27710; 17 University of Pennsylvania Medical Center, Department of Neuroscience, Abramson 516, 3400 Civic Center Boulevard, Philadelphia, Pennsylvania 19104; 18 MRI Reading Center at St. Joseph, 8216 Carrbridge Circle, Baltimore, Maryland 21204; 19 British Columbia Cancer Agency, 1515 Larch Street, Vancouver, British Columbia, Canada V6K 3N6; 20 Schering-Plough Research Institute, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 USA Summary A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m2 /day or 150 mg/m2 /day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m2 /day or 125 mg/m2 /day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. (c) 2000 Cancer Research Campaign Keywords: malignant glioma; temozolomide; procarbazine; glioblastoma multiforme 588 Received 13 August 1999 Revised 23 April 2000 Accepted 1 May 2000 Correspondence to: WKA Yung British Journal of Cancer (2000) 83(5), 588-593